Conservative Balance Sheet / Very Low LeverageExtremely low leverage (debt-to-equity ~0.7%–2.1%, ~1.7% in FY2026) provides durable financial flexibility. This allows the company to fund R&D, maintain dividends, withstand industry shocks and pursue opportunistic investments without relying on costly external financing over the next several months.
Strong And Sustainable MarginsSustained operating (~20%) and net (~14%) margins indicate durable pricing power and cost control in its specialty/generic drug business. High margins support internal funding for capital needs, buffer earnings through revenue cycles, and underpin long-term cash generation and shareholder returns.
Consistent Positive Free Cash FlowFCF remaining positive and tracking net income (~0.87–1.00x) shows the company converts earnings into cash persistently. That consistent cash generation supports dividends, organic reinvestment and financial resilience, making capital allocation decisions sustainable over the medium term.